Related Experiment Video
Updated: Jul 11, 2026
Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 11, 2013
Toxicity of platinum(II) amino acid (N,O) complexes parallels their binding to DNA as measured in a new solid phase
C J Ziegler1, K E Sandman, C H Liang
1Department of Chemistry, Massachusetts Institute of Technology, Cambridge 02139, USA.
Abstract:
The compound [Pt(lysine)Cl2] (Kplatin) was previously identified in a study of platinum amino acid complexes as a potential antitumor drug candidate. The DNA binding properties, high mobility group (HMG)-domain protein affinity for the platinated DNA, and cytotoxicity against HeLa cells of Kplatin and three related (N,O) chelated platinum(II) amino acid complexes, [Pt(arginine)Cl2] (Rplatin), K[Pt(Nepsilon-acetyllysine)Cl2] (NacKplatin), and K[Pt(norleucine)Cl2] (Norplatin), are reported. The four complexes have identical PtCl2(N,O) coordination environments. A new solid phase screening methodology was devised in which platinated DNA probes are covalently attached to a nylon support and tested for their ability to bind a fluorescently labeled HMG-domain protein. The fluorescent HMG-domain protein was generated by expressing a fusion of the green fluorescent protein (GFP) with recombinant rat HMG1. Binding revealed by the solid phase method correlated well with the results of gel mobility shift and HeLa cytotoxicity assays. These results suggest that the net charge on the complex, rather than the nature of the side chain, is the most important factor underlying the DNA binding properties and toxicity of amino acid (N,O) chelated platinum complexes. This property explains why Kplatin was previously selected from the pool of platinum amino acid complexes based on the ability of its DNA adducts to bind HMG1.
Insights
The net charge of platinum amino acid complexes, not their side chains, dictates DNA binding and antitumor activity. This finding explains Kplatin's potential as a cancer drug candidate.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Cancer Research
Background:
- Platinum-based compounds are vital in cancer chemotherapy.
- Platinum amino acid complexes offer potential alternatives with modified properties.
- Kplatin ([Pt(lysine)Cl2]) has shown promise as an antitumor agent.
Purpose of the Study:
- To investigate the DNA binding, HMG-domain protein affinity, and cytotoxicity of Kplatin and related platinum(II) amino acid complexes.
- To elucidate the structural factors influencing the biological activity of these platinum complexes.
- To develop and validate a novel solid-phase screening method for assessing DNA-protein interactions.
Main Methods:
- Synthesis and characterization of four platinum(II) amino acid complexes with identical PtCl2(N,O) coordination environments.
- Development of a solid-phase screening assay using DNA probes immobilized on nylon and a fluorescently labeled HMG-domain protein (GFP-HMG1 fusion).
- Evaluation of DNA binding using the solid-phase assay, gel mobility shift assays, and assessment of cytotoxicity against HeLa cells.
Main Results:
- A strong correlation was observed between DNA binding affinity, HMG-domain protein interaction, and cytotoxicity across the tested platinum complexes.
- The net charge of the platinum complex emerged as the primary determinant of DNA binding properties and cellular toxicity.
- The side chain structure of the amino acid ligand did not significantly influence these biological activities.
Conclusions:
- The net charge of (N,O) chelated platinum(II) amino acid complexes is a critical factor for their DNA binding and cytotoxic effects.
- This charge-dependent mechanism explains the preferential selection of Kplatin in previous studies.
- The developed solid-phase screening method provides an efficient tool for evaluating DNA-binding agents.
